Budesonide/formoterol enhances the expression of pro surfactant protein-B in lungs of COPD Patients

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Um, Soo Jung ^a,b   Lam, Stephen ^a   Coxson, Harvey ^a   Man, Shu Fan Paul ^a   Sin, Don D ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b Dong A University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; BUDESONIDE PLUS FORMOTEROL; CCL18 CHEMOKINE; CHEMOKINE; CLUB CELL SECRETORY PROTEIN 16; PROTEIN PARC; SECRETORY PROTEIN; SURFACTANT PROTEIN B; SURFACTANT PROTEIN D; UNCLASSIFIED DRUG;

ADULT; AIRWAY OBSTRUCTION; ARTICLE; BLOOD LEVEL; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFECT; DRUG RESPONSE; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; LOW DRUG DOSE; LUNG LAVAGE; MALE; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN INTERACTION; RESPIRATORY AIRFLOW; SMOKING; SYSTEMIC CIRCULATION;

AGED; BIOLOGICAL MARKERS; BRONCHOALVEOLAR LAVAGE; BUDESONIDE; DRUG INTERACTIONS; ETHANOLAMINES; FEMALE; GENE EXPRESSION REGULATION; HUMANS; LUNG; MALE; PROTEIN PRECURSORS; PROTEOLIPIDS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 84891292950     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0083881     Document Type: Article

References (23)

1. World Health Organization (2008) World Health Statistics. Available: http:// www.who.int/gho/publications/world-health-statistics/2008/en/index.html. Accessed 2013 Oct 23.
2. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, et al. (2012) Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380: 209522128.
3. Murray CJ, Lopez AD (2013) Measuring the global burden of disease. N Engl J Med 369: 4482457.
4. Barnes PJ, Chowdhury B, Kharitonov SA, Magnussen H, Page CP, et al. (2006) Pulmonary biomarkers in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 174: 6214.
5. Tzortzaki EG, Lambiri I, Vlachaki E, Siafakas NM (2007) Biomarkers in COPD. Curr Med Chem 14: 103721048.
6. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, et al. (2005) Standardisation of spirometry. Eur Respir J 26: 3192338.
7. Lam S, LeRiche JC, Kijek K (1985) Effect of filtration and concentration on the composition of bronchoalveolar lavage fluid. Chest 87: 7402742.
8. Sin DD, Man SF, Marciniuk DD, Ford G, FitzGerald M, et al. (2008) The effects of fluticasone with or without salmeterol on systemic biomarkers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 177: 120721214.
9. Hogg JC, Chu F, Utokaparch S, Woods R, Elliott WM, et al. (2004) The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 350: 264522653.
10. Pattle RE (1955) Properties, function and origin of the alveolar lining layer. Nature 175: 112521126.
11. Wright JR (2005) Immunoregulatory functions of surfactant proteins. Nat Rev Immunol 5: 58268.
12. Whitsett JA, Ohning BL, Ross G, Meuth J, Weaver T, et al. (1986) Hydrophobic surfactant-associated protein in whole lung surfactant and its importance for biophysical activity in lung surfactant extracts used for replacement therapy. Pediatr Res 20: 4602467.
13. Tokieda K, Ikegami M, Wert SE, Baatz JE, Zou Y, et al. (1999) Surfactant protein B corrects oxygen-induced pulmonary dysfunction in heterozygous surfactant protein B-deficient mice. Pediatr Res 46: 7082714.
14. Miles PR, Bowman L, Rao KM, Baatz JE, Huffman L (1999) Pulmonary surfactant inhibits LPS-induced nitric oxide production by alveolar macrophages. Am J Physiol 276: L1862196.
15. Nguyen AB, Rohatgi A, Garcia CK, Ayers CR, Das SR, et al. (2011) Interactions between smoking, pulmonary surfactant protein B, and atherosclerosis in the general population: the Dallas Heart Study. Arterioscler Thromb Vasc Biol 31: 213622143.
16. Robin M, Dong P, Hermans C, Bernard A, Bersten AD, et al. (2002) Serum levels of CC16, SP-A and SP-B reflect tobacco-smoke exposure in asymptomatic subjects. Eur Respir J 20: 115221161.
17. Pryhuber GS (1998) Regulation and function of pulmonary surfactant protein B. Mol Genet Metab 64: 2172228.
18. Phelps DS, Floros J (1991) Localization of pulmonary surfactant proteins using immunohistochemistry and tissue in situ hybridization. Exp Lung Res 17: 9852995.
19. Murray E, Khamri W, Walker MM, Eggleton P, Moran AP, et al. (2002) Expression of surfactant protein D in the human gastric mucosa and during Helicobacter pylori infection. Infect Immun 70: 148121487.
20. Rubio S, Lacaze-Masmonteil T, Chailley-Heu B, Kahn A, Bourbon JR, et al. (1995) Pulmonary surfactant protein A (SP-A) is expressed by epithelial cells of small and large intestine. J Biol Chem 270: 12162212169.
21. Vestbo J, Edwards LD, Scanlon PD, Yates JC, Agusti A, et al. (2011) Changes in forced expiratory volume in 1 second over time in COPD. N Engl J Med 365: 118421192.
22. Lomas DA, Silverman EK, Edwards LD, Miller BE, Coxson HO, et al. (2008) Evaluation of serum CC-16 as a biomarker for COPD in the ECLIPSE cohort. Thorax 63: 105821063.
23. Welte T, Miravitlles M, Hernandez P, Eriksson G, Peterson S, et al. (2009) Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 180: 7412750.